Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to “Hold” at Zacks Research

Zacks Research cut shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a strong-buy rating to a hold rating in a report published on Monday morning,Zacks.com reports.

A number of other analysts have also weighed in on SUPN. Cantor Fitzgerald increased their target price on shares of Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an “overweight” rating in a report on Tuesday, September 30th. Wall Street Zen raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Bank of America began coverage on Supernus Pharmaceuticals in a research report on Wednesday, October 29th. They issued a “buy” rating and a $65.00 price objective on the stock. Piper Sandler raised Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $40.00 to $65.00 in a research note on Thursday, October 9th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Supernus Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $63.25.

Supernus Pharmaceuticals Stock Performance

NASDAQ:SUPN opened at $46.16 on Monday. Supernus Pharmaceuticals has a fifty-two week low of $29.16 and a fifty-two week high of $57.65. The firm has a market cap of $2.65 billion, a PE ratio of -135.76, a price-to-earnings-growth ratio of 0.55 and a beta of 0.71. The business has a 50 day moving average price of $48.28 and a 200-day moving average price of $41.64.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 EPS for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.36). The firm had revenue of $170.00 million for the quarter, compared to the consensus estimate of $175.82 million. Supernus Pharmaceuticals had a negative net margin of 2.81% and a positive return on equity of 11.51%. The company’s quarterly revenue was up 9.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.69 earnings per share. Research analysts predict that Supernus Pharmaceuticals will post 2.38 EPS for the current year.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 59,900 shares of the stock in a transaction on Thursday, October 9th. The stock was sold at an average price of $50.57, for a total value of $3,029,143.00. Following the completion of the transaction, the chief executive officer owned 1,206,578 shares in the company, valued at approximately $61,016,649.46. This represents a 4.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Frank Mottola sold 5,000 shares of the business’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $45.87, for a total transaction of $229,350.00. Following the sale, the senior vice president owned 15,496 shares in the company, valued at approximately $710,801.52. This trade represents a 24.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 121,235 shares of company stock worth $5,923,797. 8.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Supernus Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Hantz Financial Services Inc. lifted its holdings in shares of Supernus Pharmaceuticals by 81.7% during the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 281 shares during the last quarter. USA Financial Formulas purchased a new stake in shares of Supernus Pharmaceuticals in the 3rd quarter worth approximately $50,000. Smartleaf Asset Management LLC raised its stake in Supernus Pharmaceuticals by 30.8% during the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock valued at $54,000 after buying an additional 268 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Supernus Pharmaceuticals in the first quarter worth $41,000. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new stake in Supernus Pharmaceuticals in the first quarter worth $46,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.